COVID-19
COVID-19 Biorepository
Year Started: 2019
COVID-19 biorepository is a longitudinal disease-based cohort study. Eligible to participate were all patients with a laboratory diagnosis of COVID-19 (including children and pregnant women). In total, around 2,000 COVID-19 participants were recruited and followed up for one year. The follow-up time points were weekly while consented participants were hospitalized or under isolation in quarantine facilities, and monthly follow-ups after disease recovery, for a year. Data and biological samples were collected, with access to the participants' medical records. Recruitment of the infected population is completed. COVID-19 biorepository study extends its objectives to collect information about the immunization process against SARS-CoV-2 (coronavirus) in Qatar. Consenting participants will be asked to complete a face to face questionnaire, and provide biological samples at different time points: 1) before vaccination, 2) before the second dose of the vaccine, 3) 2 to 3 weeks after the last dose of vaccine, 4) every 3 months after the last dose of the vaccine for a period of 1 year.
- Access:
- Open to applicants
- Type:
- Cohort
- Status:
- In progress
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
Biomarker datasets | 0 - 3 months |
Clinical records | 3 - 6 months |
Followup records | 0 - 3 months |
Freezer temperature logs | 0 - 3 months |
Genomic datasets | 3 - 6 months |
Imaging data | 0 - 3 months |
Pre-analytical data | 3 - 6 months |
Physiological/biochemical measurements | 0 - 3 months |
Primary care records | 3 - 6 months |
Quality indicators | 0 - 3 months |
Survey data | 0 - 3 months |
Treatment records | 3 - 6 months |
Psychological data | 3 - 6 months |
Participant Ethnicity | 0 - 3 months |
Both sexes
Adult (> 40 years)
1001 - 3000 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Microscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Buffy coat | -85°C to -60°C | N/A | Not applicable | ||
Nasal washing | -85°C to -60°C | N/A | Not applicable | ||
Isolated peripheral blood mononuclear cells (viable) | Liquid nitrogen | N/A | Not applicable | ||
Plasma (double spun) | -85°C to -60°C | N/A | Not applicable | ||
Saliva | -85°C to -60°C | N/A | Not applicable | ||
Urine (random) | -85°C to -60°C | N/A | Not applicable | ||
Other | -85°C to -60°C | N/A | Not applicable | ||
Host genomic DNA (Derivative) | -85°C to -60°C | N/A | Not applicable | ||
Serum | -85°C to -60°C | N/A | Not applicable |